세계의 색소침착증 치료 시장 : 치료 유형별, 증상별 - 예측(2024-2032년)

Hypopigmentation disorder treatment market size is likely to register 6.1% CAGR between 2024 to 2032, driven by increasing awareness about skin health and the rising prevalence of skin conditions, such as vitiligo and albinism. As per data from the Global Vitiligo Foundation (GVF), around 70 million people globally suffer from vitiligo. Growing advancements in medical technology and dermatological research are also contributing significantly to the expansion of treatment options available for hypopigmentation disorders.

Lately, the adoption of innovative treatment modalities like laser therapy, phototherapy, and skin grafting techniques has picked significant ground . Rising collaborations between pharmaceutical companies and research institutions for the development of novel therapeutic interventions are leading to the diversification of treatment options, further adding to the industry growth.

The hypopigmentation disorder treatment industry is classified on the basis of treatment type, diseases indication and region.

In terms of treatment type, the market size from the procedures segment is anticipated to witness notable growth rate through 2032, favored by the advancements in dermatological procedures, such as laser therapy, skin grafting, and micropigmentation techniques. The increasing preference for minimally invasive procedures among patients has resulted in the growing acceptance of aesthetic treatments. The expanding base of dermatology clinics and cosmetic surgery centers equipped with state-of-the-art equipment and skilled healthcare professionals is expected to drive the segment growth.

Based on disease indication, the hypopigmentation disorder treatment market from the vitiligo segment will expand through 2032. This is driven by the increasing prevalence of vitiligo worldwide, coupled with the growing awareness about the condition. Rapid advancements in medical research have led to the development of novel therapies specifically targeting vitiligo, including topical treatments. Rising initiatives by healthcare organizations and advocacy groups to reduce stigma associated with the condition will favor the market growth.

Asia Pacific hypopigmentation disorder treatment industry will witness decent growth between 2024-2032, attributed to the large population along with rising disposable incomes, and increasing healthcare expenditures. The prevalence of skin conditions, such as vitiligo and melasma is notably high in several countries across the APAC. Growing advancements in medical technology and healthcare infrastructure, particularly in countries like China, Japan, and South Korea, will contribute to the accessibility and adoption of advanced treatment modalities, subsequently stimulating the regional market growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing adoption of advanced skin care procedures
    • 3.2.1.2 Increasing prevalence of hypopigmentation disorders
    • 3.2.1.3 Growing expenditure on dermatological treatments
    • 3.2.1.4 Rising awareness regarding skin health among younger population
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of cosmetic procedures
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
  • 3.6.1 Supplier power
  • 3.6.2 Buyer power
  • 3.6.3 Threat of new entrants
  • 3.6.4 Threat of substitutes
  • 3.6.5 Industry rivalry
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Drugs
  • 5.2.1 By type
    • 5.2.1.1 Corticosteroids
    • 5.2.1.2 Melanocyte-stimulating hormone
    • 5.2.1.3 Other drugs
  • 5.2.2 By route of administration
    • 5.2.2.1 Oral
    • 5.2.2.2 Topical
    • 5.2.2.3 Other routes of administrations
  • 5.2.3 By distribution channel
    • 5.2.3.1 Hospital pharmacies
    • 5.2.3.2 Retail pharmacies
    • 5.2.3.3 Online pharmacies
• 5.3 Procedures
  • 5.3.1 By type
    • 5.3.1.1 Laser treatment
    • 5.3.1.2 Phototherapy
    • 5.3.1.3 Microdermabrasion
    • 5.3.1.4 Other procedures
  • 5.3.2 By end-user
    • 5.3.2.1 Hospitals
    • 5.3.2.2 Dermatology clinics
    • 5.3.2.3 Aesthetic centers
    • 5.3.2.4 Other end-users

Chapter 6 Market Estimates and Forecast, By Disease Indication, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Vitiligo
• 6.3 Albinism
• 6.4 Other disease indications

Chapter 7 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 7.1 Key trends, by region
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 UK
  • 7.3.3 France
  • 7.3.4 Spain
  • 7.3.5 Italy
  • 7.3.6 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 Japan
  • 7.4.2 China
  • 7.4.3 India
  • 7.4.4 Australia
  • 7.4.5 Rest of Asia Pacific
• 7.5 Latin America
  • 7.5.1 Brazil
  • 7.5.2 Mexico
  • 7.5.3 Rest of Latin America
• 7.6 Middle East and Africa
  • 7.6.1 South Africa
  • 7.6.2 Saudi Arabia
  • 7.6.3 Rest of Middle East and Africa

Chapter 8 Company Profiles

• 8.1 AbbVie Inc.
• 8.2 Aclaris Therapeutics, Inc.
• 8.3 Bayer AG
• 8.4 Candela Corporation
• 8.5 Galderma
• 8.6 Incyte
• 8.7 Novartis AG
• 8.8 Pfizer Inc.
• 8.9 Pierre Fabre group
• 8.10 Shiseido Company Limited
• 8.11 UNIZA Group